▲ 1.53%
prev close
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Congressional Trades
7
All tracked trades
Members Trading
3
Unique members
Net Activity
-1
3 buys · 4 sells
Members Who Traded This Stock
7 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-30 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 132d ago | — | |
| 2025-09-25 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 162d ago | — | |
| 2025-07-22 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 232d ago | — | |
| 2025-06-11 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 232d ago | — | |
| 2025-03-24 | NVSNovartis AG Common Stock | Sell | $100,001 - $250,000 | 344d ago | — | |
| 2023-07-10 | NVSNovartis AG Common Stock | Sell | $50,001 - $100,000 | 963d ago | — | |
| 2023-03-31 | NVSNovartis AG Common Stock | Buy | $50,001 - $100,000 | 1081d ago | — |
2025-10-30
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
132d ago
2025-09-25
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
162d ago
2025-07-22
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
232d ago
2025-06-11
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
232d ago
2025-03-24
George Whitesides
NVS
Amount
$100,001 - $250,000
Filed
344d ago
2023-07-10
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
963d ago
2023-03-31
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
1081d ago
Recent News
Powered by Polygon.io
Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More
Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-30 · Purchase
$1,001 - $15,000
Lisa McClain
2025-09-25 · Sale
$1,001 - $15,000
Lisa McClain
2025-07-22 · Sale
$1,001 - $15,000
Lisa McClain
2025-06-11 · Purchase
$1,001 - $15,000
George Whitesides
2025-03-24 · Sale
$100,001 - $250,000
Daniel Goldman
2023-07-10 · Sale
$50,001 - $100,000
Daniel Goldman
2023-03-31 · Purchase
$50,001 - $100,000